Sensitive detection of BRAF gene mutation is key to a cure

By BIORON Diagnostics

With medical advancements being made in the treatment of metastatic melanoma, Bioron Diagnostics has come up with a system that enables the robust sensitive detection of mutations at the BRAF gene associated with sensitivity of melanoma cells to inhibitors of the BRAF kinase. Such breakthroughs could help to significantly increase the survival rates of cancer patients by allowing the use of efficient target therapy.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.